Nephros, Inc. (NASDAQ:NEPH) Sees Significant Drop in Short Interest

Nephros, Inc. (NASDAQ:NEPHGet Free Report) saw a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 5,000 shares, a decline of 30.6% from the January 15th total of 7,200 shares. Based on an average trading volume of 10,900 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.1% of the company’s shares are sold short.

Nephros Price Performance

Shares of NEPH traded down $0.04 during mid-day trading on Friday, reaching $1.52. 45,495 shares of the company’s stock traded hands, compared to its average volume of 9,885. The stock has a market cap of $16.02 million, a P/E ratio of -16.89 and a beta of 1.19. The stock’s 50-day moving average is $1.56 and its two-hundred day moving average is $1.64. Nephros has a 12 month low of $1.36 and a 12 month high of $3.73.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nephros stock. Topline Capital Management LLC purchased a new stake in Nephros, Inc. (NASDAQ:NEPHFree Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 419,887 shares of the company’s stock, valued at approximately $617,000. Topline Capital Management LLC owned 3.98% of Nephros as of its most recent filing with the Securities and Exchange Commission (SEC). 41.10% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Benchmark reissued a “speculative buy” rating and set a $5.00 price objective on shares of Nephros in a research note on Tuesday, November 12th.

Get Our Latest Stock Analysis on NEPH

Nephros Company Profile

(Get Free Report)

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

Featured Stories

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.